Journal: Diagnostics

Article Title: Altered Expression of C4BPA and CXCL1 Genes in the Endometrium of Patients with Recurrent Implantation Failure after In Vitro Fertilization and Thin Endometrium

doi: 10.3390/diagnostics14171967

Figure Lengend Snippet: Comparative gene expression statistics between RIF and fertile women.

Article Snippet: Quantitative PCR was performed in duplicate using ready-made primers and hydrolysis probes from the TaqManTM Gene Expression Assay (Thermo Fisher Scientific, assay IDs: Hs00426339_m1, Hs01115665_m1, Hs00173634_m1, Hs00174103_m1, Hs02800695_m1, Hs00233987_m1, Hs00989291_m1, Hs00236937_m1, Hs01003716_m1, Hs00232769_m1, Hs02786624_g1, and Hs01122445_g1) and TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific), under the conditions recommended by the manufacturer, on the StepOnePlus Real-Time PCR System (Thermo Fisher Scientific).

Techniques: Gene Expression

Journal: Diagnostics

Article Title: Altered Expression of C4BPA and CXCL1 Genes in the Endometrium of Patients with Recurrent Implantation Failure after In Vitro Fertilization and Thin Endometrium

doi: 10.3390/diagnostics14171967

Figure Lengend Snippet: Differences in gene expression levels (ΔCq values) in endometrial tissue between RIF patients and fertile women: ( a ) CXCL1 gene; ( b ) C4BPA gene.

Article Snippet: Quantitative PCR was performed in duplicate using ready-made primers and hydrolysis probes from the TaqManTM Gene Expression Assay (Thermo Fisher Scientific, assay IDs: Hs00426339_m1, Hs01115665_m1, Hs00173634_m1, Hs00174103_m1, Hs02800695_m1, Hs00233987_m1, Hs00989291_m1, Hs00236937_m1, Hs01003716_m1, Hs00232769_m1, Hs02786624_g1, and Hs01122445_g1) and TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific), under the conditions recommended by the manufacturer, on the StepOnePlus Real-Time PCR System (Thermo Fisher Scientific).

Techniques: Gene Expression

Journal: Diagnostics

Article Title: Altered Expression of C4BPA and CXCL1 Genes in the Endometrium of Patients with Recurrent Implantation Failure after In Vitro Fertilization and Thin Endometrium

doi: 10.3390/diagnostics14171967

Figure Lengend Snippet: ROC analysis results.

Article Snippet: Quantitative PCR was performed in duplicate using ready-made primers and hydrolysis probes from the TaqManTM Gene Expression Assay (Thermo Fisher Scientific, assay IDs: Hs00426339_m1, Hs01115665_m1, Hs00173634_m1, Hs00174103_m1, Hs02800695_m1, Hs00233987_m1, Hs00989291_m1, Hs00236937_m1, Hs01003716_m1, Hs00232769_m1, Hs02786624_g1, and Hs01122445_g1) and TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific), under the conditions recommended by the manufacturer, on the StepOnePlus Real-Time PCR System (Thermo Fisher Scientific).

Techniques:

Journal: Diagnostics

Article Title: Altered Expression of C4BPA and CXCL1 Genes in the Endometrium of Patients with Recurrent Implantation Failure after In Vitro Fertilization and Thin Endometrium

doi: 10.3390/diagnostics14171967

Figure Lengend Snippet: ROC curves for potential markers and combinations of markers in discriminating RIF patients from fertile women: ( a ) CXCL1 ; ( b ) C4BPA ; ( c ) combination of CXCL1 and C4BPA .

Article Snippet: Quantitative PCR was performed in duplicate using ready-made primers and hydrolysis probes from the TaqManTM Gene Expression Assay (Thermo Fisher Scientific, assay IDs: Hs00426339_m1, Hs01115665_m1, Hs00173634_m1, Hs00174103_m1, Hs02800695_m1, Hs00233987_m1, Hs00989291_m1, Hs00236937_m1, Hs01003716_m1, Hs00232769_m1, Hs02786624_g1, and Hs01122445_g1) and TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific), under the conditions recommended by the manufacturer, on the StepOnePlus Real-Time PCR System (Thermo Fisher Scientific).

Techniques:

Journal: Cell Death & Disease

Article Title: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

doi: 10.1038/s41419-026-08588-2

Figure Lengend Snippet: A Bar plot showing fold-change expression of proteins identified in the secretome. B Bar plot showing protein levels of vimentin, EFEMP1 and C4BPA in FAPs secretome from healthy aged-matched controls ( n = 4) and DMD patients ( n = 6) analysed by ELISA. C Dot-plot showing EFEMP1 and C4BPA levels in serological samples from healthy aged-matched controls ( n = 16) and DMD patients ( n = 24) analysed by ELISA. Paired t-test was used to analyse. D Bar-plot showing the relative mRNA levels of C4BPA analysed in cells ( n = 2). E Western-blot results of C4BPA and GAPDH expression in muscle tissue from healthy controls ( n = 2) and DMD patients ( n = 2), and in FAP cells from healthy controls ( n = 3) and DMD patients ( n = 4). F Representative images of muscle histology from a healthy control young boy and a DMD patient stained with C4BPA, laminin and PDGFRα. Scale bar: 50 µm. and bar plot showing the area of C4BPA expressed in the IF tissue staining from healthy controls ( n = 3) and DMD patients ( n = 3). Data are shown as means ± SD; Results were statistically analysed using paired t-test analysis. Statistical significance was set at P < 0.05; ** P < 0.01; *** P < 0.001.

Article Snippet: The C4BPA siRNA, 5’-GCAAGUAGAGAUUAAGACAdTdT-3’ and MISSION® siRNA Universal Negative Control were synthesized by Merck Life Science.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Western Blot, Control, Staining

Journal: Cell Death & Disease

Article Title: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

doi: 10.1038/s41419-026-08588-2

Figure Lengend Snippet: A Timeline scheme of the differentiation of myoblasts with C4BPA treatment. B Bar plot showing the % area of myotubes and the ratio of nuclei/myotube of untreated and treated myoblasts with C4BPA after the differentiation process. C Myotube size graph and fiber size frequency in untreated and treated myoblasts with C4BPA after the differentiation process. D Bar plot showing the proliferation data after 24, 48 and 72 h. E Graphs showing different migratory parameters (mean-speed, median speed, total distance, linearity of forward progression and trajectory path of myoblasts after 72 h in culture. F Relative expression genes analysed after the differentiation process in non-treated and C4BPA-treated myoblasts. Data are represented as the mean of three replicates ± standard error of the mean. Results were statistically analysed using Mann-Whitney U. Statistical significance was set at P < 0.05. ** P < 0.01; *** P < 0.001.

Article Snippet: The C4BPA siRNA, 5’-GCAAGUAGAGAUUAAGACAdTdT-3’ and MISSION® siRNA Universal Negative Control were synthesized by Merck Life Science.

Techniques: Expressing, MANN-WHITNEY

Journal: Cell Death & Disease

Article Title: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

doi: 10.1038/s41419-026-08588-2

Figure Lengend Snippet: A Timeline scheme of the differentiation of the 3D culture with C4BPA treatment. B Representative cross-sectional image of a 3D muscle, untreated and treated with C4BPA. Staining corresponds to SAA, F-actinin and nuclei of tissues. C Bar graph showing myotube cross-section area (µm2) and Feret diameter (µm) after 10 days myoblasts differentiation with and without C4BPA treatment. D Bar graph showing the total number of myotubes measured per mm 2 or by tissue. E Bar graph showing contractile dynamics of the 3D muscle tissue after 10 days of differentiation. Twitch force (µN/mm2), tetanic force (µN/mm2), tetanic/twitch index, time in peak (seconds) and time to peak (seconds) parameters were measured. Data are shown as means ± SD; Statistical significance was set at P < 0.05, ** P < 0.01.

Article Snippet: The C4BPA siRNA, 5’-GCAAGUAGAGAUUAAGACAdTdT-3’ and MISSION® siRNA Universal Negative Control were synthesized by Merck Life Science.

Techniques: Staining

Journal: Cell Death & Disease

Article Title: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

doi: 10.1038/s41419-026-08588-2

Figure Lengend Snippet: A Diagram scheme of the indirect co-culture of C4BPA siRNA-transfected FAPs with healthy myoblasts. B Relative expression of C4BPA mRNA levels after transfection ( n = 1). C Dot plot showing the differentiation index of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. D Dot plot showing the number of nuclei per myotube of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. E % of myotubes per field measured by MHCII staining after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. F Representative immunostaining of the indirect co-culture system analysed at the end of the differentiation process after FAPs transfection. Data are shown as means ± SD; Statistical significance was set at P < 0.05. ** P < 0.01; *** P < 0.001.

Article Snippet: The C4BPA siRNA, 5’-GCAAGUAGAGAUUAAGACAdTdT-3’ and MISSION® siRNA Universal Negative Control were synthesized by Merck Life Science.

Techniques: Co-Culture Assay, Transfection, Expressing, Cell Culture, Staining, Immunostaining

Journal: Journal of Ovarian Research

Article Title: Development and clinical validation of a seven-gene signature based on tumor stem cell-related genes to predict ovarian cancer prognosis

doi: 10.1186/s13048-023-01326-8

Figure Lengend Snippet: Multivariate cox analysis of 7-mRNA signature

Article Snippet: Subsequently, the TMA slides were incubated with anti-C4BPA antibody (1:50 dilution; LifeSpan Biosciences, LS-C253165), GALP antibody (1:30 dilution; Sigma, HPA053938), CACNA1C antibody (1:200 dilution; Proteintech, 21,774–1-AP), PENK antibody (1:50 dilution; Sigma, HPA013138), PSMA2 antibody (1:100 dilution; Proteintech,14,377–1-AP), CXCL9 antibody (1:50 dilution; Proteintech, 22,355–1-AP), COL16A1 antibody (1: 50 dilution; LifeSpan Biosciences, LS-C198822), and left overnight at 4 °C.

Techniques:

Journal: Brain : a journal of neurology

Article Title: Extracellular vesicle biomarkers for complement dysfunction in schizophrenia.

doi: 10.1093/brain/awad341

Figure Lengend Snippet: Figure 2 Characteristics of EV-derived complement DEPs in patients with schizophrenia. (A) Comparison of C3 expression between patients with schizophrenia (SZ) and healthy controls (HC). *P = 0.039, Cohen's d = 0.78. (B) Comparison of C4A expression. ***P < 0.001, Cohen's d = 1.57. (C) Comparison of C4B expression. ***P < 0.001, Cohen's d = 1.24. (D) Comparison of C4BPA expression. **P = 0.0029, Cohen's d = 1.17. (E) Comparison of C4BPB expression. *P = 0.0129, Cohen's d = 0.88. (F) Comparison of PROS1 expression. ***P < 0.001, Cohen's d = 1.20. Although the levels of body mass index (BMI) and diastolic blood pressure (DBP) were significantly different between patients and controls, they did not demonstrate significant correlations with the levels of extracellular vesicle (EV)-derived complement associated components within each independent group. Hence, they were not adjusted as covariates. (G and H) The heat map of correlation analysis between EV-derived non-differentially expressed proteins (DEPs) and DEPs in the complement network and the disease course. Significant correlation was defined as absolute R values ≥0.4 and P-value <0.05 [−log10 (P) > 1.3]. Pearson or Spearman correlation was used as appropriate. (I) Box plot of the absolute R value of correlation analysis. **P = 0.0015, Cohen's d = 1.67. (J–L) Expression levels of NOE1, KIRR3 and LMO4 mRNA in different tissues; their mRNA expression were mostly enriched in brain. Data were extracted from the Human Protein Atlas. (M) Heat map of linear correlation results between the EV-derived complement DEPs and brain enriched proteins of NOE1, KIRR3 and LMO4 in patients and healthy controls. The number in each box and the legend represent the R-value. *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: Primary antibodies of C3 (21337-1-AP), C4 (22233-1-AP), C4BPA (11819-1-AP) and PROS1 (16910-1-AP) were used, which were all purchased from Proteintech Group, Inc.

Techniques: Derivative Assay, Comparison, Expressing

Journal: Brain : a journal of neurology

Article Title: Extracellular vesicle biomarkers for complement dysfunction in schizophrenia.

doi: 10.1093/brain/awad341

Figure Lengend Snippet: Figure 3 Potential biomarkers validated in EVs in patients with schizophrenia and healthy controls. The concentration of extracellular vesicle (EV)-derived complement differentially expressed proteins were detected by proteomics (Set 1) and Mesoscale Discovery technology (Set 2). (A and B) C3 amount in EVs. Set 1: *P = 0.039, Cohen's d = 0.78. Set 2: **P < 0.001, Cohen's d = 1.13. (C and D) C4 amount in EVs. Set 1: ***P < 0.001, Cohen's d = 1.36. C4 intensity was the combination of C4A and C4B intensity. Set 2: *P = 0.019, Cohen's d = 0.67. (E and F) C4BPA amount in EVs. Set 1: **P = 0.003, Cohen's d = 1.17. Set 2: ***P < 0.001, Cohen's d = 2.04. (G and H) PROS1 amount in EVs. Set 1: ***P < 0.001, Cohen's d = 1.20. Set 2: **P = 0.0023, Cohen's d = 0.90. Although the levels of body mass index or diastolic blood pressure were significantly different between patients (SZ) and controls (HC), they did not demonstrate significant correlations with the levels of complement-associated components within each independent group. Hence, they were not adjusted as covariates. (I–L) Western blot analysis of the activation of EV-derived Complement C3 and C4. Neoepitope-specific antibodies of C3a and C4a were used. Human serum purified proteins of C3a des Arg and C4a des Arg were used as the positive controls. The last lane of each membrane was the positive control. n = 11 for each group. SZ = schizophrenia; HC = healthy controls.

Article Snippet: Primary antibodies of C3 (21337-1-AP), C4 (22233-1-AP), C4BPA (11819-1-AP) and PROS1 (16910-1-AP) were used, which were all purchased from Proteintech Group, Inc.

Techniques: Concentration Assay, Derivative Assay, Western Blot, Activation Assay, Purification, Membrane, Positive Control

Journal: Brain : a journal of neurology

Article Title: Extracellular vesicle biomarkers for complement dysfunction in schizophrenia.

doi: 10.1093/brain/awad341

Figure Lengend Snippet: Figure 4 Potential biomarkers validated in plasma in patients with schizophrenia and healthy controls. The concentration of complement differen tially expressed proteins in plasma were detected by ELISA. (A and B) Plasma concentration of C3. Set 1: P = 0.16, Cohen's d = 0.43. Set 2: P = 0.22, Cohen's d = 0.35. (C and D) Plasma concentration of C4. Set 1: P = 0.76, Cohen's d = 0.0005. Set 2: P = 0.72, Cohen's d = 0.098. (E and F) Plasma concentration of C4BPA. Set 1: P = 0.25, Cohen's d = 0.35. Set 2: *P = 0.03, Cohen's d = 0.27. (G and H) Plasma concentration of PROS1. Set 1: **P = 0.001, Cohen's d = 1.11. Set 2: P = 0.87, Cohen's d = 0.02. Although the levels of body mass index or diastolic blood pressure were significantly different between patients and controls, they did not demonstrate significant correlations with the levels of complement associated components within each independent group. Consequently, they were not adjusted as covariates. SZ = schizophrenia; HC = healthy controls; n.s. = not significant.

Article Snippet: Primary antibodies of C3 (21337-1-AP), C4 (22233-1-AP), C4BPA (11819-1-AP) and PROS1 (16910-1-AP) were used, which were all purchased from Proteintech Group, Inc.

Techniques: Clinical Proteomics, Concentration Assay, Enzyme-linked Immunosorbent Assay